MD
Therapeutic Areas
AnaptysBio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ANB033 | Celiac Disease, Eosinophilic Esophagitis | Phase 1 |
| Rosnilimab (ANB030) | Rheumatoid Arthritis | Phase 2b |
| ANB101 | Undisclosed Inflammatory Indications | Phase 1 |
Leadership Team at AnaptysBio
DF
Daniel Faga
President & CEO
DM
Dennis Mulroy
Chief Financial Officer
PF
Paul F. Lizzul
Chief Medical Officer
EL
Eric Loumeau
Chief Legal Officer
MD
Martin Dahl
SVP, Research
CS
Cailin Sibley
SVP, Translational Medicine
BS
Ben Stone
Chief Business Officer
PR
Priya Raina
SVP, Clinical Operations
BM
Beth Mueller
SVP, Human Resources
DM
David McKeon
SVP, Controller